Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case–control study
Authors:
- Marcel E CurlinMCMarcel E Curlin
- Farah Cassis-GhavamiFCFarah Cassis-Ghavami
- Amalia S MagaretAMAmalia S Magaret
- Gregory A SpiesGSGregory A Spies
- Ann DuerrADAnn Duerr
- Connie L CelumCCConnie L Celum
- Jorge L SanchezJSJorge L Sanchez
- Joseph B MargolickJMJoseph B Margolick
- Roger DetelsRDRoger Detels
- M Juliana McElrathMMM Juliana McElrath
- Lawrence CoreyLCLawrence Corey
- 14 January 2011
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 25 (2) , 153-158
Abstract
Adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. We performed a nested case–control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. In MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8–1.5, P = 0.57) and 1.0 (95% confidence interval 0.4–2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. The presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection.Keywords
This publication has 22 references indexed in Scilit:
- Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humansNature Medicine, 2009
- Baseline Ad5 serostatus does not predict Ad5 HIV vaccine–induced expansion of adenovirus-specific CD4+ T cellsNature Medicine, 2009
- Post-Step modifications for research on HIV vaccinesAIDS, 2009
- Activation of a dendritic cell–T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cellsJournal of Experimental Medicine, 2008
- HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisThe Lancet, 2008
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of aPlasmodium falciparumProtein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1Infection and Immunity, 2008
- The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?Journal of Experimental Medicine, 2008
- Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and DJournal of Virology, 2007